Cancer Stem Cell News Volume 2.05 | Feb 6 2013

PUBLICATIONS (Ranked by impact factor of the journal)

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Epithelial-mesenchymal transition (EMT) of adherent epithelial cells to a migratory mesenchymal state has been implicated in tumor metastasis in preclinical models. To investigate its role in human cancer, researchers characterized EMT in circulating tumor cells from breast cancer patients. [Science]
Abstract | Press Release

Expression of Intercellular Adhesion Molecule-1 by Hepatocellular Carcinoma Stem Cells and Circulating Tumor Cells
Intercellular adhesion molecule-1 (ICAM1) is believed to be involved in metastasis of hepatocellular carcinoma (HCC) cells. Researchers investigated whether ICAM1 is a marker of HCC stem cells. [Gastroenterology] Abstract

miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells by Modulating KLF4
Scientists found that cancer stem-like cells (CSCs) (CD24^–/CD44⁺/ESA⁺) isolated from metastatic breast cell lines are significantly more metastatic than non-CSC populations in an organ-specific manner. [Cancer Res] Abstract | Press Release

A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer
Researchers report a CD90+ cell population found in esophageal squamous cell carcinoma which is endowed with stem cell-like properties and high tumorigenic and metastatic potential. [Cancer Res] Abstract

Lmo2 Induces Hematopoietic Stem Cell Like Features in T-Cell Progenitor Cells Prior to Leukemia
LIM domain Only 2 (Lmo2) is frequently deregulated in sporadic and gene therapy-induced acute T-cell lymphoblastic leukemia where its overexpression is an important initiating mutational event. Researchers analyzed proliferation, differentiation, and cell death in CD2-Lmo2 transgenic thymic progenitor cells to understand the cellular effects of enforced Lmo2 expression. [Stem Cells] Abstract

Resistance to DNA-Damaging Treatment in Non-Small Cell Lung Cancer Tumor-Initiating Cells Involves Reduced DNA-PK/ATM Activation and Diminished Cell Cycle Arrest
Increasing evidence suggests that tumor-initiating cells, also called cancer stem cells, are partly responsible for resistance to DNA-damaging treatment. Researchers addressed if such a phenotype may contribute to radio- and cisplatin resistance in non-small cell lung cancer. [Cell Death Dis] Full Article

Peroxisome Proliferator Activated Receptor-α/Hypoxia Inducible Factor-1α Interplay Sustains Carbonic Anhydrase IX and Apoliprotein E Expression in Breast Cancer Stem Cells
Investigators report on the relationship between nuclear receptors activity and the modulation of the pro-inflammatory phenotype in breast cancer stem cells. [PLoS One] Full Article

Evaluation of Characteristics of CD44⁺CD117⁺ Ovarian Cancer Stem Cells in Three Dimensional Basement Membrane Extract Scaffold versus Two Dimensional Monocultures
The authors demonstrated that human epithelial ovarian cancer CD44⁺CD117⁺ cells possessed the properties of cancer stem cells that exhibited more chemoresistance in the three-dimensional culture than that of in two-dimensional one. [BMC Cell Biol] Full Article

Stem Cell Therapeutics Announces Agreement with Trillium Therapeutics Inc. for Merger
Stem Cell Therapeutics Corp. announced the execution of a Letter of Agreement with Trillium Therapeutics Inc. of Toronto, under which Trillium would be merged into Stem Cell Therapeutics Corp. (SCT) by way of a three-cornered amalgamation or plan of arrangement with a newly-created SCT subsidiary. [Stem Cell Therapeutics Corp.] Press Release

ImmunoCellular Therapeutics’ Investigational New Drug (IND) Application for ICT-140 Allowed by the FDA
ImmunoCellular Therapeutics, Ltd. announced that the US Food and Drug Administration (FDA) has allowed the IND application for ICT-140, paving the way for conducting a clinical trial. ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer stem cells. [ImmunoCellular Therapeutics, Ltd.] Press Release

Verastem Initiates Phase I/Ib Clinical Trial of VS-6063 Plus Paclitaxel for Patients with Ovarian Cancer
Verastem, Inc. announced the initiation of a Phase I/Ib trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer. [Verastem, Inc.] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Danish Stem Cell Society (DASCS) 2^nd Symposium 2013
March 7, 2013
Copenhagen, Denmark

NEW Cell Reprogramming Australia (CRA) – Frontiers in Cell Reprogramming
May 6-7, 2013
Brisbane, Australia

Visit our events page to see a complete list of events in the cancer stem cell community.

Postdoctoral Fellow – Cancer Biology and Stem Cell (University of Texas at Houston, Medical School)

Postdoctoral Fellow – Myeloproliferative Neoplasms (Mount Sinai Medical Center)

Postdoctoral Scientist – Defining and Targeting Leukemic Stem Cells in Acute Leukemia (University of Oxford)

Postdoctoral Fellow – Breast Cancer Stem Cells (University of Cincinnati College of Medicine)

Faculties in Cancer Biology & Immunotherapy (Huzhou University School of Medicine)

Faculty Position – Mammalian Epigenetics and Genome Biology (Cornell University)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.